← Back to Analyst Consensus 
CRBU Buy
Caribou Biosciences, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 4 downgrades / 0 reiterations from 4 firms
Next Earnings
Nov 9, 2026 (13 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 8, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Oct 7, 2026 | Brookline Capital | downgrade | Buy → Hold | — | 38% |
| Oct 7, 2026 | RBC Capital | downgrade | Outperform → Sector Perform | — | 55% |
| Oct 7, 2026 | Leerink Partners | downgrade | Outperform → Market Perform | — | 51% |
| Aug 14, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| May 11, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 7, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 9, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Feb 2, 2026 | Clear Street | initiate | — → Buy | $13 | 47% |
| Nov 5, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| Nov 3, 2025 | Citigroup | maintain | Buy → Buy | $8 | 54% |
| Apr 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $3 | 44% |
| Mar 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Jan 7, 2025 | B of A Securities | maintain | Buy → Buy | $11 | 53% |
| Nov 26, 2024 | Citigroup | maintain | Buy → Buy | $6 | 54% |
| Nov 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Sep 3, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Aug 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Aug 7, 2024 | RBC Capital | reiterate | Outperform → Outperform | $14 | 55% |
| Jul 17, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Jun 4, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| May 16, 2024 | Truist Securities | maintain | Buy → Buy | $19 | 54% |
| May 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $24 | 44% |
| Mar 19, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $24 | 44% |
| Mar 12, 2024 | RBC Capital | reiterate | Outperform → Outperform | $19 | 55% |
| Nov 8, 2023 | Cantor Fitzgerald | initiate | — → Neutral | $0 | 50% |
| Jul 26, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $23 | 44% |
| Jul 14, 2023 | Truist Securities | reiterate | Buy → Buy | $23 | 54% |
| Jul 11, 2023 | Truist Securities | initiate | — → Buy | $23 | 54% |
| May 10, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $25 | 44% |
| Mar 14, 2023 | HC Wainwright & Co. | maintain | — → Buy | $26 | 44% |
| Mar 10, 2023 | RBC Capital | reiterate | — → Outperform | $19 | 55% |
| Mar 10, 2023 | Oppenheimer | maintain | — → Outperform | $32 | 52% |
| Aug 29, 2022 | Citigroup | maintain | — → Buy | $38 | 54% |
| Aug 18, 2022 | HC Wainwright & Co. | maintain | — → Buy | $27 | 44% |
| Aug 10, 2022 | RBC Capital | maintain | — → Outperform | $19 | 55% |
| May 13, 2022 | Citigroup | maintain | — → Buy | $39 | 54% |
| May 12, 2022 | SVB Leerink | maintain | — → Outperform | $34 | — |
| May 10, 2022 | SVB Leerink | maintain | — → Outperform | $30 | — |
| Mar 22, 2022 | SVB Leerink | maintain | — → Outperform | $29 | — |
| Feb 18, 2022 | RBC Capital | initiate | — → Outperform | $22 | 55% |
| Feb 14, 2022 | Brookline Capital | initiate | — → Buy | $19 | 38% |
| Dec 1, 2021 | Oppenheimer | initiate | — → Outperform | $36 | 52% |
| Nov 30, 2021 | HC Wainwright & Co. | initiate | — → Buy | $28 | 44% |
| Nov 15, 2021 | Citigroup | upgrade | Neutral → Buy | $27 | 54% |
| Aug 17, 2021 | Citigroup | initiate | — → Neutral | $27 | 54% |
| Aug 17, 2021 | B of A Securities | initiate | — → Buy | $30 | 53% |
| Aug 17, 2021 | SVB Leerink | initiate | — → Outperform | $32 | — |
Price Target Trend
May 17, 2026 Oct 27, 2026
EPS Estimates
0q —
0y —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days